Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar 3:10:57-66.
doi: 10.2147/CEG.S110547. eCollection 2017.

Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis

Robin J Dart  1   2   3 , Mark A Samaan  1 , Nick Powell  1   4 , Peter M Irving  1
Affiliations
Review

Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis

Robin J Dart et al. Clin Exp Gastroenterol. .

Abstract

Ulcerative colitis (UC) is a chronic relapsing and remitting inflammatory bowel disease, with a characteristic leukocytic infiltration of the mucosa. Immunosuppression including anti-TNF-α therapy is a mainstay of treatment for many; however, systemic immunosuppression is not universally effective and is associated with potential side effects. The gut-tropic integrin α4β7, which is expressed on leukocytes, mediates migration from the circulation to the intestinal mucosa. Vedolizumab is a monoclonal antibody which blocks the egress of leukocytes via α4β7, preventing accumulation in the mucosa, and attenuating inflammation without systemic immunosuppression. Vedolizumab has been evaluated in UC in a phase III trial, demonstrating efficacy as both an induction and a maintenance agent. In this article, we review the clinical trial data and also explore the growing body of "real-world" effectiveness data, investigating response and remission rates of vedolizumab in clinical practice. In addition, we review the increasing volume of data supporting the reassuring safety profile associated with vedolizumab.

Keywords: personalized therapy; ulcerative colitis; vedolizumab.

PubMed Disclaimer

Conflict of interest statement

Disclosure Mark A Samaan has received advisory board fees from Hospira and lecture fees from Hospira, Takeda, and MSD. Nick Powell has received advisory board fees from Abbvie, Allergan, Debiopharm International, Ferring, and Vifor Pharma and lecture fees from Allergan and Falk Pharma. Peter M Irving has received lecture fees from Abbvie, Warner Chilcott, Ferring, Falk Pharma, Takeda, MSD, Janssen, Shire, and Tillotts; financial support for research from MSD and Takeda and Janssen; and advisory board fees from Abbvie, Warner Chilcott, Takeda, MSD, Vifor Pharma, Pharmacosmos, Topivert, Genentech, Hospira, Samsung Bioepis, Janssen, and VH2. Robin J Dart reports no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Clinical effectiveness studies of vedolizumab in ulcerative colitis. Notes: *At week 14, **data not available for steroid-free remission.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119–124. - PMC - PubMed
    1. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146(6):1489–1499. - PMC - PubMed
    1. Rogler G, Vavricka S. Exposome in IBD: recent insights in environmental factors that influence the onset and course of IBD. Inflammatory Bowel Diseases. 2015;21(2):400–408. - PubMed
    1. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study) Scand J Gastroenterol. 2009;44(4):431–440. - PubMed
    1. Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol. 1996;31(3):260–266. - PubMed

LinkOut - more resources